Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 37% Improvement Relative Risk Case, close contact 52% HCQ for COVID-19  Becetti et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 700 patients in Qatar (April - July 2020) Fewer cases with HCQ (not stat. sig., p=0.17) c19hcq.org Becetti et al., Qatar Medical J., August 2022 Favors HCQ Favors control

Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar

Becetti et al., Qatar Medical Journal, doi:10.5339/qmj.2022.37
Aug 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Retrospective 700 patients with autoimmune rheumatic disease in Qatar, showing lower risk of COVID-19 with HCQ use, without statistical significance. For patients having close contact with COVID-19 cases, there was a statistically significant association with HCQ use and lower risk of COVID-19 in unadjusted results.
risk of case, 36.8% lower, RR 0.63, p = 0.17, treatment 26 of 314 (8.3%), control 49 of 386 (12.7%), NNT 23, adjusted per study, odds ratio converted to relative risk, multivariable.
risk of case, 52.0% lower, RR 0.48, p < 0.001, treatment 16 of 46 (34.8%), control 29 of 40 (72.5%), NNT 2.7, patients with close contact to cases, close contact.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Becetti et al., 5 Aug 2022, retrospective, Qatar, peer-reviewed, mean age 43.2, 12 authors, study period 1 April, 2020 - 31 July, 2020. Contact: becettikarima@gmail.com.
This PaperHCQAll
Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar
Karima Becetti, Eman Satti, Betsy Varughese, Yousef Al Rimawi, Rawan Sheikh Saleh, Nawal Hadwan, Miral H Gharib, Mohamed Awni Al Kahlout, Essa Abuhelaiqa, Hadil Afif Ashour, Rajvir Singh, Samar Al Emadi
Qatar Medical Journal, doi:10.5339/qmj.2022.37
Background: Autoimmune rheumatic diseases (ARDs) are characterized by immune dysfunction and associated with an increased risk of infections, which were of significant concern during the coronavirus disease 2019 (COVID-19) pandemic. Variable rates of COVID-19 incidence have been reported in patients with ARDs; however, the true effect of this infection on this patient population is still unclear. We, therefore, aimed to evaluate the COVID-19 prevalence among a multiethnic cohort of patients with ARDs in Qatar. Material and Methods: We used telephonic surveys to collect demographic and clinical information of patients with ARD in Qatar between April 1 and July 31, 2020, including any close contact with a COVID-19 case at home or work and polymerase chain reaction (PCR)-confirmed COVID-19 diagnosis. An electronic medical records review was conducted to verify pertinent data collected through the surveys. Prevalence with 95% confidence interval (CI), Student's t-tests, and chi-square/Fisher's exact tests were used for univariate analyses, whereas multivariate logistic regression was used to identify factors associated with COVID-19. Results: The study included 700 patients with ARD (mean age, 43.2 ^12.3 years), and 73% were female. Until July 2020, 75 (11%, 95% CI 9% -13%) patients had COVID-19. Factors associated with COVID-19 included being a man (adjusted odds ratio [aOR] 2.56, 95% CI 1.35-4.88, p ¼ 0.01) and having close contact with a COVID-19 case (aOR 27.89, 95% CI 14.85-52.38, p ¼ 0.01). Disease severity and rheumatic medications had no significant
References
Akiyama, Hamdeh, Micic, Sakuraba, Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and metaanalysis, Ann Rheum Dis. Published online, doi:10.1136/annrheumdis-2020-218946
Alattar, Shaar, Othman, Coronavirus disease 2019 in solid organ transplant recipients in a setting of proactive screening and contact tracing, Qatar Med J, doi:10.5339/jemtac.2021.qhc.3
Aries, Iking-Konert, No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany), Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218400
Bosch, Guilabert, Pallarés, Cerveral, Ramos-Casals et al., Infections in systemic lupus erythematosus: A prospective and controlled study of 110 patients, Lupus, doi:10.1177/0961203306071919
Bozzalla Cassione, Zanframundo, Biglia, Codullo, Montecucco et al., COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217717
Conticini, Bargagli, Bardelli, Rana, Baldi et al., COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217681
Cross, Smith, Hoy, Carmona, Wolfe et al., The global burden of rheumatoid arthritis: Estimates from the Global Burden of Disease 2010 study, Ann Rheum Dis, doi:10.1136/annrheumdis-2013-204627
Doran, Crowson, Pond, 'fallon, Gabriel, Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study, Arthritis Rheum, doi:10.1002/art.10524
Emmi, Bettiol, Mattioli, Silvestri, Scala et al., SARS-CoV-2 infection among patients with systemic autoimmune diseases, Autoimmun Rev, doi:10.1016/j.autrev.2020.102575
England, Roul, Yang, Kalil, Michaud et al., Risk of COVID-19 in rheumatoid arthritis: a National Veterans affairs matched cohort study in at-risk individuals, Arthritis Rheumatol, doi:10.1002/art.41800
Favalli, Ingegnoli, Cimaz, Caporali, What is the true incidence of COVID-19 in patients with rheumatic diseases?, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217615
Ferri, Giuggioli, Raimondo, 'andolina, Tavoni et al., COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series, Clin Rheumatol, doi:10.1007/s10067-020-05334-7
Fitzgerald, Mecoli, Douglas, Harris, Aravidis et al., Risk factors for infection and health impacts of the Covid-19 pandemic in people with autoimmune diseases, medRxiv
Landewé, Machado, Kroon, Bijlsma, Burmester et al., EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217877
Macías, González-Moreno, Sánchez-García, Morillo-Verdugo, Venegas et al., Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases Becetti et al, QATAR MEDICAL JOURNAL
Mehta, Pedro, Ozen, Kalil, Wolfe et al., Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: A US national cohort study, RMD Open, doi:10.1136/rmdopen-2019-000935
Michelena, Borrell, López-Corbeto, López-Lasanta, Moreno et al., Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs, Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2020.05.001
Mikuls, Co-morbidity in rheumatoid arthritis, Best Pract Res Clin Rheumatol, doi:10.1016/S1521-6942(03)00041-X
Mikuls, Johnson, Fraenkel, Arasaratnam, Baden et al., American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2, Arthritis Rheumatol, doi:10.1002/art.41437
Monti, Balduzzi, Delvino, Bellis, Quadrelli et al., Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis
Murtas, Andreano, Gervasi, Guido, Consolazio et al., Association between autoimmune diseases and COVID-19 as assessed in both a testnegative case-control and population case-control design, Autoimmun Highlights, doi:10.1186/s13317-020-00141-1
Omrani, Almaslamani, Daghfal, The first consecutive 5000 patients with COVID-19 disease 2019 in Qatar; a nation-wide cohort study, medRxiv, doi:10.1101/2020.07.15.20154690
Ouédraogo, Tiendrébéogo, Kaboré, Ntsiba, COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments, Clin Rheumatol, doi:10.1007/s10067-020-05189-y
Pablos, Abasolo, Alvaro-Gracia, Blanco, Blanco et al., Prevalence of hospital PCRconfirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217763
Quartuccio, Valent, Pasut, Tascini, Vita, Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy, Jt Bone Spine, doi:10.1016/j.jbspin.2020.05.003
Ramirez, Gerosa, Beretta, Bellocchi, Argolini et al., COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients, Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2020.06.012
Ramirez, Moroni, Della-Torre, Gerosa, Beretta et al., Systemic lupus erythematosus and COVID-19: what we know so far, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218601
Salvarani, Mancuso, Gradellini, Viani, Pandolfi et al., Susceptibility to COVID-19 in patients treated with antimalarials: a population-based study in Emilia-Romagna, Northern Italy, Arthritis Rheumatol, doi:10.1002/art.41475
Sattui, Liew, Graef, Coler-Reilly, Berenbaum et al., Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19, Expert Rev Clin Immunol, doi:10.1080/1744666x.2020.1792778
Silman, Pearson, Epidemiology and genetics of rheumatoid arthritis, Arthritis Res, doi:10.1186/ar578
Smitten, Choi, Hochberg, Suissa, Simon et al., The risk of hospitalized infection in patients with rheumatoid arthritis, J Rheumatol
Stokes, Zambrano, Anderson, Marder, Raz et al., Coronavirus disease 2019 case surveillance-United States, MMWR, doi:10.15585/mmwr.mm6924e2
Tektonidou, Wang, Dasgupta, Ward, Burden of serious infections in adults with systemic lupus erythematosus: A national population-based study, 1996-2011, Arthritis Care Res, doi:10.1002/acr.22575
Wolfe, Mitchell, Sibley, Fries, Bloch et al., The mortality of rheumatoid arthritis, Arthritis Rheum, doi:10.1002/art.1780370408
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Xu, Chen, Wang, Feng, Zhou et al., Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, Sci China Life Sci
Zhong, Shen, Yang, Huang, Chen et al., COVID-19 in patients with rheumatic disease in Hubei Province, China: a multicentre retrospective observational study, Lancet Rheumatol, doi:10.1016/s2665-9913(20)30227-7
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit